Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

America and Europe.

The company's second Phase 3 trial, VITAL-2, is a multi-center, randomized, controlled Phase 3 clinical trial designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. VITAL-2 was initiated in June 2005 and is currently enrolling patients at approximately 90 sites in North America and Europe. The company expects to complete enrollment of approximately 600 patients in the first half of 2009 and if this is achieved, to have a sufficient number of events for a pre-planned interim analysis at that time.

The U.S. Food and Drug Administration (FDA) granted Cell Genesys Special Protocol Assessments (SPAs) for both VITAL-1 and VITAL-2. The SPA is a process that allows for official FDA evaluation of a Phase 3 clinical trial and provides trial sponsors with a binding written agreement that the design and analysis of the study are adequate to support a license application submission if that study is performed according to the SPA. Cell Genesys completed the modifications requested by FDA during the review process.

About GVAX Cancer Immunotherapies

GVAX cancer immunotherapies are non patient-specific investigational therapeutics comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and then irradiated for safety. GVAX is designed to be administered through intradermal injections on an outpatient basis. To date, over 600 patients have been treated with GVAX cancer immunotherapies in Phase 1 and Phase 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GV
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: Global Coatings for ... This report analyzes the ... US$ Million by the following Product Segments: Active ... The report provides separate comprehensive analytics for the ...
(Date:8/20/2014)... Mich. and PHOENIX ... corporation established to bring cutting-edge next-generation sequencing and ... cancer patients, today announced a collaboration with TESARO, ... to characterize patient tissue samples from clinical trials ... or resistant to TESARO,s TSR-011.  This may lead to ...
(Date:8/20/2014)... CITY , Aug. 20, 2014 ApolloDx™ ... mobile diagnostic platform during a special event at the ... , on September 5, 2014. The event, which ... on the ApolloDx website, www.apollodx.com .    ... diagnostic testing," said Jared Bauer , Co-Founder and ...
Breaking Medicine Technology:Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... FLORHAM PARK, N.J., March 24, 2011 Managed Health Care ... on alternate site health care providers, announced the completion of ... results of which were released at the 2011 MHA Long ... Nevada. This study was first introduced in ...
... CHICAGO, March 24, 2011 When it comes to ... According to a January 2011 survey by the American ... avoid losing their natural teeth. One way to help ... treatment. During Root Canal Awareness Week, March 27 – ...
Cached Medicine Technology:Managed Health Care Associates, Inc. (MHA) Released Results of Fourth Annual Independent Long Term Care Member Study with Highlights of Specialty Pharmaceutical Product Utilization 2Dispelling Myths of Root Canals Through Education 2
(Date:8/21/2014)... Baltimore, MD 21218 (PRWEB) August 21, 2014 ... company dedicated to aging interventions and addressing ... proposes a new concept, OncoFinder, for signalome-wide ... for accurate and robust cross-platform analysis of ... , The original research, published in the ...
(Date:8/20/2014)... Illinois (PRWEB) August 21, 2014 On September ... The Walk MS organization connects people living with MS with ... two million dollars and are 85% of the way to ... Junction City, registration begins at 11:30 and the walk starts ... will be available to answer question about chiropractic care and ...
(Date:8/20/2014)... 21, 2014 PAINWeek, the National ... that Ethan Nadelmann, JD, PhD, will deliver the ... the founder and executive director of the Drug ... States promoting alternatives to the war on drugs. ... both domestically and internationally, he has played a ...
(Date:8/20/2014)... August 21, 2014 Top10BestSEOHosting.com is ... reviews about hosting products. It is headed by ... experience. The site offers research-based information and factual ... suppliers in the current market. , Recently, ... announced that GoDaddy and Bluehost are ...
(Date:8/20/2014)... A new trend in the insurance ... before issuing an approximate quote for insurance coverage, according ... helping the public to obtain life insurance quotes without ... http://quotespros.com/life-insurance.html . , The coverage industry has changed ... appeared in many U.S. states. Some consumers are now ...
Breaking Medicine News(10 mins):Health News:OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis 2Health News:Dr. Kelch of AlignLife North Peoria Supports Peoria Annual Walk MS 2Health News:PAINWeek Welcomes Ethan Nadelmann, JD, PhD, as Keynote Speaker at 2014 Conference 2Health News:New Reviews For Linux Web Hosting Suppliers Announced By Top10BestSEOHosting.com 2Health News:Life Insurance Quotes Without Medical Exams Now Displayed to Adults at Insurance Website 2
... Chief Science Officer Geri Dawson, Ph.D. and Assistant VP, Head of ... Hour: The Doctors Are In," a monthly live web chat with ... from 3:00 - 4:00 pm Eastern / 12:00 noon - 1:00 ... time of the web chat, viewers simply log in via the ...
... Salamon HealthDay Reporter , WEDNESDAY, Dec. 7 ... developing breast cancer by avoiding unnecessary medical radiation, forgoing ... don,t need to worry about using hair dyes or ... the body of research on environmental factors that may ...
... California,s low-income seniors with disabilities are struggling to remain in ... and may be slashed even further, according to a new ... with support from The SCAN Foundation. Should ... to In-Home Supportive Services (IHSS) on Dec. 15, as proposed ...
... NY)An antimalarial agent developed by researchers at Albert ... effective at clearing infections caused by the malaria parasite ... parasites to death. The novel research, carried out on ... to develop more potent therapies against one of the ...
... the main cause of complications and death from cancer. For ... development of these metastases themselves, instead of focusing on the ... a team from the Swiss Center for Experimental Cancer Research ... plays a major role in metastasis development, and showed that ...
... Fla. -- The use of two drugs never tried in ... 70 percent destruction of cancer cells already resistant to commonly ... Florida . Their report, published online in Gynecologic ... might offer a much needed treatment option for women with ...
Cached Medicine News:Health News:New Autism Speaks 'Office Hour: The Doctors Are In' monthly live web chat 2Health News:Expert Panel Pinpoints Environmental Culprits in Breast Cancer 2Health News:Expert Panel Pinpoints Environmental Culprits in Breast Cancer 3Health News:Expert Panel Pinpoints Environmental Culprits in Breast Cancer 4Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 2Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 4Health News:Novel drug wipes out deadliest malaria parasite through starvation 2Health News:Novel drug wipes out deadliest malaria parasite through starvation 3Health News:Nipping metastases in the bud 2Health News:Mayo Clinic researchers find drug duo kills chemotherapy-resistant ovarian cancer cells 2
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical...
... Prodisc design is based upon the ... natural spinal motion segment unit. Kinematics ... integrates the biomechanical and anatomical aspects ... concept: Three implant components utilizing proven ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int...
Designed for use during surgical procedures under fluoroscopy. A very practical unit, the frames superior design eliminates problems associated with imaging....
Medicine Products: